223 results
SD
EX-1.01
ABBV
Abbvie Inc
31 May 24
Conflict minerals disclosure
4:05pm
supply AbbVie with materials containing 3TG for the Products. AbbVie surveyed the majority of these suppliers, excluding those reporting no 3TG use
PX14A6G
Chevedden John
26 Mar 24
Letter to shareholders
2:31pm
of this proposal topic being on the ABBV ballot for the next 10-years.
Written materials are submitted pursuant to Rule 14a-6(g)(1) promulgated under the Securities … ; the shareholder is not able to vote your proxies, nor does this communication contemplate such an event.
The shareholder asks all shareholders to vote by following the procedural instructions provided in the proxy materials.
DEFA14A
ABBV
Abbvie Inc
18 Mar 24
Additional proxy soliciting materials
4:17pm
Materials
Soliciting Material under §240.14a-12
AbbVie Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement … , if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
No fee required.
Fee paid previously with preliminary materials
8-K
EX-1.1
pbbd0 wqupot4
26 Feb 24
Other Events
5:08pm
424B5
wkw1f2tt xbf
26 Feb 24
Prospectus supplement for primary offering
6:12am
424B5
kh3dnx9l2g
21 Feb 24
Prospectus supplement for primary offering
8:39am
8-K
EX-99.2
vfm7u2bw
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.1
sg6cl7cea6rt
6 Dec 23
AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
5:28pm
8-K
EX-99.2
tflt0k z5hpurxxsh48l
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
8-K
EX-99.1
cq3 vwjcr
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
8:47am
SD
EX-1.01
ejm40nft o0yesnl9t
31 May 23
Conflict minerals disclosure
4:59pm